Epigenetic Alterations Upstream and Downstream of P53 Signaling in Colorectal Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Aug 27

PMID 34439227

Citations 8

Authors

Maja T Tomicic

Mona Dawood

Thomas Efferth

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) belongs to the most common tumor types, and half of all CRC harbor missense mutations in the tumor suppressor gene. In addition to genetically caused loss of function of p53, epigenetic alterations (DNA methylation, histone modifications, micro-RNAs) contribute to CRC development. In this review, we focused on epigenetic alterations related to the entire p53 signaling pathway upstream and downstream of p53. Methylation of genes which activate p53 function has been reported, and methylation of and was associated with increased mutation rates of . The micro-RNA 34a activates and was methylated in CRC. Proteins that regulate TP53 DNA methylation, mutations, and acetylation of TP53-related histones were methylated in CRC. P53 regulates the activity of numerous downstream proteins. Even if is not mutated, the function of wildtype p53 may be compromised if corresponding downstream genes are epigenetically inactivated. Thus, the role of p53 for CRC development, therapy response, and survival prognosis of patients may be much more eminent than previously estimated. Therefore, we propose that novel diagnostic devices measuring the entirety of genetic and epigenetic changes in the "p53 signalome" have the potential to improve the predictive and prognostic power in CRC diagnostics and management.

Citing Articles

Integrated Analysis of Somatic DNA Variants and DNA Methylation of Tumor Suppressor Genes in Colorectal Cancer.

Nishiki H, Ura H, Togi S, Hatanaka H, Fujita H, Takamura H Int J Mol Sci. 2025; 26(4).

PMID: 40004106 PMC: 11855003. DOI: 10.3390/ijms26041642.

Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53.

Taritsa I, Fossel E Front Pharmacol. 2025; 16:1529483.

PMID: 39944631 PMC: 11813898. DOI: 10.3389/fphar.2025.1529483.

Bioengineered Anthocyanin-Enriched Tomatoes: A Novel Approach to Colorectal Cancer Prevention.

Suzauddula M, Kobayashi K, Park S, Sun X, Wang W Foods. 2024; 13(18).

PMID: 39335919 PMC: 11430996. DOI: 10.3390/foods13182991.

Amelioration effect of 18β-Glycyrrhetinic acid on methylation inhibitors in hepatocarcinogenesis -induced by diethylnitrosamine.

Khalil H, Nada A, Mahrous H, Hassan A, Rijo P, A Ibrahim I Front Immunol. 2024; 14:1206990.

PMID: 38322013 PMC: 10844948. DOI: 10.3389/fimmu.2023.1206990.

Anti-Colorectal Cancer Activity of Solasonin from L. via Histone Deacetylases-Mediated p53 Acetylation Pathway.

Lan X, Lu M, Fang X, Cao Y, Sun M, Shan M Molecules. 2023; 28(18).

PMID: 37764423 PMC: 10534604. DOI: 10.3390/molecules28186649.

References

Cha Y, Kim K, Han S, Rhee Y, Bae J, Wen X . Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer. 2016; 115(2):164-71. PMC: 4947699. DOI: 10.1038/bjc.2016.176. View

Salama R, Sadaie M, Hoare M, Narita M . Cellular senescence and its effector programs. Genes Dev. 2014; 28(2):99-114. PMC: 3909793. DOI: 10.1101/gad.235184.113. View

Condelli V, Calice G, Cassano A, Basso M, Rodriquenz M, Zupa A . Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas. Cancers (Basel). 2021; 13(1). PMC: 7796477. DOI: 10.3390/cancers13010158. View

Nyiraneza C, Sempoux C, Detry R, Kartheuser A, Dahan K . Hypermethylation of the 5' CpG island of the p14ARF flanking exon 1β in human colorectal cancer displaying a restricted pattern of p53 overexpression concomitant with increased MDM2 expression. Clin Epigenetics. 2012; 4(1):9. PMC: 3470942. DOI: 10.1186/1868-7083-4-9. View

Li J, Chu M, Wang S, Chan D, Qi S, Wu M . Identification and characterization of nardilysin as a novel dimethyl H3K4-binding protein involved in transcriptional regulation. J Biol Chem. 2012; 287(13):10089-10098. PMC: 3323043. DOI: 10.1074/jbc.M111.313965. View

Obata T, Toyota M, Satoh A, Sasaki Y, Ogi K, Akino K . Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res. 2003; 9(17):6410-8. View

Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M . MicroRNAs in the DNA Damage/Repair Network and Cancer. Int J Genomics. 2014; 2014:820248. PMC: 3926391. DOI: 10.1155/2014/820248. View

Toyota M, Suzuki H . Epigenetic drivers of genetic alterations. Adv Genet. 2010; 70:309-23. DOI: 10.1016/B978-0-12-380866-0.60011-3. View

Jin L, Hanigan C, Wu Y, Wang W, Park B, Woster P . Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. Biochem J. 2012; 449(2):459-68. PMC: 3525012. DOI: 10.1042/BJ20121360. View

10.

Barlev N, Liu L, Chehab N, Mansfield K, Harris K, Halazonetis T . Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2002; 8(6):1243-54. DOI: 10.1016/s1097-2765(01)00414-2. View

11.

Advani S, Advani P, DeSantis S, Brown D, VonVille H, Lam M . Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis. Transl Oncol. 2018; 11(5):1188-1201. PMC: 6080640. DOI: 10.1016/j.tranon.2018.07.008. View

12.

Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K . CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2016; 21(6):1091-1101. DOI: 10.1007/s10147-016-1017-6. View

13.

Wang G, Cao X, Lai S, Luo X, Feng Y, Wu J . Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer. Oncogene. 2014; 34(7):912-21. DOI: 10.1038/onc.2014.30. View

14.

Muller F, Tora L . Chromatin and DNA sequences in defining promoters for transcription initiation. Biochim Biophys Acta. 2013; 1839(3):118-28. DOI: 10.1016/j.bbagrm.2013.11.003. View

15.

Cohen S, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G . Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Clin Colorectal Cancer. 2015; 15(2):164-9. PMC: 4864501. DOI: 10.1016/j.clcc.2015.10.005. View

16.

Popat S, Hubner R, Houlston R . Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005; 23(3):609-18. DOI: 10.1200/JCO.2005.01.086. View

17.

Zhang L, Lu Q, Chang C . Epigenetics in Health and Disease. Adv Exp Med Biol. 2020; 1253:3-55. DOI: 10.1007/978-981-15-3449-2_1. View

18.

Cai S, Wang J, Zeng W, Cheng X, Liu L, Li W . Lysine-specific histone demethylase 1B (LSD2/KDM1B) represses p53 expression to promote proliferation and inhibit apoptosis in colorectal cancer through LSD2-mediated H3K4me2 demethylation. Aging (Albany NY). 2020; 12(14):14990-15001. PMC: 7425427. DOI: 10.18632/aging.103558. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Konishi K, Issa J . Targeting aberrant chromatin structure in colorectal carcinomas. Cancer J. 2007; 13(1):49-55. DOI: 10.1097/PPO.0b013e31803c72fe. View